Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Depreciation: 2015-2024

  • Intellia Therapeutics' Accumulated Depreciation rose 24.66% to $49.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $49.7 million, marking a year-over-year increase of 24.66%. This contributed to the annual value of $49.7 million for FY2024, which is 24.66% up from last year.
  • Intellia Therapeutics' Accumulated Depreciation amounted to $49.7 million in Q4 2024, which was up 24.66% from $39.9 million recorded in Q4 2023.
  • In the past 5 years, Intellia Therapeutics' Accumulated Depreciation ranged from a high of $49.7 million in Q4 2024 and a low of $19.3 million during Q4 2020.
  • Moreover, its 3-year median value for Accumulated Depreciation was $39.9 million (2023), whereas its average is $40.9 million.
  • Data for Intellia Therapeutics' Accumulated Depreciation shows a peak YoY soared of 39.39% (in 2020) over the last 5 years.
  • Over the past 5 years, Intellia Therapeutics' Accumulated Depreciation (Quarterly) stood at $19.3 million in 2020, then spiked by 35.09% to $26.1 million in 2021, then climbed by 27.13% to $33.2 million in 2022, then increased by 20.07% to $39.9 million in 2023, then increased by 24.66% to $49.7 million in 2024.
  • Its Accumulated Depreciation was $49.7 million in Q4 2024, compared to $39.9 million in Q4 2023 and $33.2 million in Q4 2022.